Malignant neoplasm of stomach
|
0.660 |
GeneticVariation
|
disease |
BEFREE |
SNP rs56288038 (C/G) in IRF-1 3'UTR was involved in the occurrence of GC by acting as a tumor promoter factor.
|
27866197 |
2016 |
Malignant neoplasm of stomach
|
0.660 |
GeneticVariation
|
disease |
BEFREE |
The interferon regulatory factor-1 (IRF1) gene, localized on chromosome 5q31.1, is mutated or rearranged in several cancers including some hematopoietic and gastric cancers.
|
19697121 |
2010 |
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
UNIPROT |
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer.
|
9679752 |
1998 |
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
BEFREE |
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer.
|
9679752 |
1998 |
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
BEFREE |
SNP rs56288038 (C/G) in IRF-1 3'UTR was involved in the occurrence of GC by acting as a tumor promoter factor.
|
27866197 |
2016 |
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
UNIPROT |
Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding.
|
10395927 |
1999 |
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Involved in regulation of differentiation and proliferation, IRF-1 acts as a tumor suppressor gene and is inactivated by deletion of its one or more exons (exon skipping) in many hematological malignancies, including acute myelocytic leukemia (AML) and myelodysplastic syndromes (MDS).
|
21790247 |
2011 |
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
We have investigated the allelic loss of IRF1 in a group of 12 patients with MDS and a 5q deletion and 2 patients with AML and a 5q deletion.
|
8219215 |
1993 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells.
|
11264190 |
2001 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We did not detect integration of the IRF-1 gene in the DNA of any tumors derived from the CML patient samples, and also we detected no expression of human IRF-1 mRNA.
|
8795694 |
1996 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Many of the MDS-derived cell lines carry cytogenetic and molecular genetic abnormalities typically associated with MDS: gain or loss of all or parts of chromosomes 5, 7, 8 and 20 (-5/5q-, -7/7q-, + 8, 20q-); alterations of oncogenes and tumor suppressor genes (IRF-1, p15, p16, p53, RAS, RB).
|
10654445 |
2000 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SNP rs56288038 (C/G) in IRF-1 3'UTR was involved in the occurrence of GC by acting as a tumor promoter factor.
|
27866197 |
2016 |
Platelet Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
New gene functions in megakaryopoiesis and platelet formation.
|
22139419 |
2011 |
Platelet Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
New gene functions in megakaryopoiesis and platelet formation.
|
22139419 |
2011 |
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe).
|
20978265 |
2011 |
fibrinogen activity
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe).
|
20978265 |
2011 |
Fibrinogen, CTCAE
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe).
|
20978265 |
2011 |
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We have investigated the allelic loss of IRF1 in a group of 12 patients with MDS and a 5q deletion and 2 patients with AML and a 5q deletion.
|
8219215 |
1993 |
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The interferon regulatory factor 1 (IRF-1) gene is located at 5q31, the site of common deletions in myelodysplastic syndromes (MDS) and secondary leukemias.
|
10807049 |
2000 |
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Many of the MDS-derived cell lines carry cytogenetic and molecular genetic abnormalities typically associated with MDS: gain or loss of all or parts of chromosomes 5, 7, 8 and 20 (-5/5q-, -7/7q-, + 8, 20q-); alterations of oncogenes and tumor suppressor genes (IRF-1, p15, p16, p53, RAS, RB).
|
10654445 |
2000 |
MYELODYSPLASTIC SYNDROME
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Involved in regulation of differentiation and proliferation, IRF-1 acts as a tumor suppressor gene and is inactivated by deletion of its one or more exons (exon skipping) in many hematological malignancies, including acute myelocytic leukemia (AML) and myelodysplastic syndromes (MDS).
|
21790247 |
2011 |
Carcinogenesis
|
0.080 |
GeneticVariation
|
phenotype |
BEFREE |
Deletions, mutations or aberrant splicing of IRF-1 would result in its functional inactivation, and closely related to the tumorigenesis.
|
28039033 |
2017 |
Malignant neoplasm of breast
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We now report that the A4396G single nucleotide polymorphism in the IRF1 gene is more frequent in human breast cancer cell lines than in the general population (P = 0.01).
|
17498560 |
2007 |
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
IRF-1 gene rearrangements may be a crucial point in the pathogenesis of some cancer types.
|
11846974 |
2002 |
Hepatitis C
|
0.070 |
GeneticVariation
|
disease |
LHGDN |
Our findings suggest the possibility that the -300AA IRF-1 genotype is associated with outcome in patients with HCV genotype 3 infection.
|
16894313 |
2006 |